Here's the article someone had asked for
Piper Jaffray analyst Edward Tenthoff reiterated an Overweight rating and $7 price target on Idera Pharmaceuticals (NASDAQ: IDRA) calling it their Top Small Cap Pick into the 2nd-half.
Tenthoff comments, "Idera is a fundamentally transformed RNA medicine play with multiple value drivers in 2H:14 and into 2015. The primary drivers are Phase I/II studies of IMO-8400 in Waldenstrom lymphoma, which are underway with data around year-end, and Diffuse
Large B-Cell Lymphoma (DLBCL) with data in early 2015. Idera intends to start Phase II studies of IMO-8400 in orphan autoimmune indications polymyositis, dermatomyositis and Graft-vs.-Host Disease (GvHD) in 2H:14."
He added, "Idera has also developed a new Gene Silencing Oligonucleotide (GSO) platform that can create future RNA medicines and
partnering opportunities. The company ended 2Q:14 with cash of $64 million, which we estimate is sufficient to fund operations into 2016."
Were they passed around form hedge fund to hedge fund like a hot potato?
Was some short seller renting them out and telling them how they were of no value?
Do they know Eduardo's shares? Do they miss them?
Now they can rest and be loved.
56th Annual Meeting of the American Society of Hematology
December 6-9, 2014; San Francisco, Calif.
IMO-8400, an Antagonist of Toll-like Receptors 7, 8, and 9, in Development for Genetically Defined B-Cell Lymphomas: Safety and Activity in Phase 1 and Phase 2 Clinical Trials
Session name: 624. Lymphoma: Therapy with Biologic Agents, excluding Pre-Clinical Models: Poster II
Poster presentation time: Sunday, December 7, 2014, 6:00 - 8:00 p.m. PST
Novel Approach to the Potential Treatment of Patients with B-Cell Lymphomas Harboring the MYD88 L265P Mutation: Combination Treatment with TLR Antagonist and Rituximab
Session name: 625. Lymphoma: Pre-Clinical – Chemotherapy and Biologic Agents I
Oral presentation time: Monday, December 8, 2014, 3:30 p.m. PST
About half as ready for life-changing gains as last year.
Remember all of that "institutional" AH action last week @ $2.91? That was me. I like the breakout during the day and figured correctly it was gone, gone, gone.
Interesting times, and more irons in the fire than this time last year.
Great news or elaborate pump and dump?
Idera has added too many quality industry experts for it to be the latter, IMO.
that some people with a lot of money want to own this stock.
We now return to your normal programming.
Last year there was one big event on the immediate horizon, the IMO-8400 for Psoriasis test. Instead of it being a miracle cure,. it was just a safety trial as designed.
Now there are more indications for which the pipeline is being considered or trialed for, a new CEO who has had industry success, and some new encouraging results, including for IMO-2055.
More shots on goal and a better goaltender.
Why does everything look rose-colored?
It's going up.
Or maybe it was added to an index or two like a lot of baby biotechs. Look at charts of TTPH, CEMP, AGIO,
I like your theories better as far as intent of the buyers. But in any case, the stock is in firmer hands.
IMO-2055 monotherapy and IMO-2055 and ipilimumab combination therapy showed potent antitumor activity in multiple preclinical models
In addition, combination therapy overcame immune tolerance and demonstrated improved antitumor activity versus monotherapy with either agent
These data support further evaluation of combination regimens with IMO-2055 and CTLA-4 mAbs or possibly other checkpoint inhibitor
I've posted the link the the Idera Investors Club
In the presentation at the AACR meeting, Idera scientists summarized the results of several studies of IMO-2055 alone and in combination with ipilimumab in well-established preclinical models of bladder, colon and lung cancer.
Results showed that intratumoral injections of IMO-2055 inhibited the growth of treated and distant tumors, as evaluated by tumor volume and histology. Compared to monotherapy with either agent, the combination regimen involving intratumoral injections of both agents demonstrated increased and sustained inhibition of treated and distant tumor growth.
In addition, there were statistically significant increases in cytotoxic T cells against two antigens (AH1 and β-gal) expressed in treated and distant tumors, respectively, for the combination therapy versus monotherapy with either agent.
Yes, and the ISIS connection is not lost on me.
it is showing a last trade of 10.25 with a low of 3.955 and a high of 12.34, volume of 2,905,707
Well maybe you could start to help everyone else! Buena suerte. Spider sense tells me it is time for IDRA to move again. Options to 80 is really interesting.